Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 11/20 | 0.58 |
| ▸ | CDK1 | P06493 | 1/20 | 0.58 |
| ▸ | CDK2 | P24941 | 1/20 | 0.58 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.47 |
| ▸ | PRKAB2 | O43741 | 7/20 | 0.46 |
| ▸ | PRKAG1 | P54619 | 7/20 | 0.46 |
| ▸ | PRKAA2 | P54646 | 7/20 | 0.46 |
| ▸ | PRKAA1 | Q13131 | 7/20 | 0.46 |
| ▸ | PRKAG3 | Q9UGI9 | 7/20 | 0.46 |
| ▸ | PRKAG2 | Q9UGJ0 | 7/20 | 0.46 |
| ▸ | PRKAB1 | Q9Y478 | 7/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4497832 | 0.87 | GSK3B (0.61) | GSK3BCDK1CDK2CYP1A2PRKAB2 | |
| SCHEMBL4502136 | 0.83 | GSK3B (0.60) | GSK3BCDK1CDK2CYP1A2PRKAB2 | |
| SCHEMBL4483090 | 0.81 | GSK3B (0.55) | GSK3BCDK1CDK2AAK1CYP1A2 | |
| SCHEMBL4496851 | 0.81 | GSK3B (0.55) | GSK3BCDK1CDK2CYP1A2PRKAB2 | |
| SCHEMBL4497307 | 0.81 | GSK3B (0.57) | GSK3BCDK1CDK2CYP1A2PRKAB2 | |
| SCHEMBL2334591 | 0.79 | GSK3B (0.60) | GSK3BCDK1CDK2AAK1 | |
| SCHEMBL4493589 | 0.79 | GSK3B (0.54) | GSK3BCDK1CDK2CYP1A2PRKAB2 | |
| SCHEMBL1460820 | 0.79 | GSK3B (0.57) | GSK3BCDK1CDK2CYP1A2PRKAB2 | |
| SCHEMBL4492488 | 0.78 | GSK3B (0.53) | GSK3BCDK1CDK2CYP1A2PRKAB2 | |
| SCHEMBL4503512 | 0.78 | GSK3B (0.55) | GSK3BCDK1CDK2CYP1A2PRKAB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1537087-B1 | NOVEL AMINOINDAZOLE DERIVATIVES AS MEDICINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | AVENTIS PHARMA SA (FR) | 2012-11-28 | — | — | EP | claimed |
| US-7166629-B2 | Aminoindazole derivatives as medicaments and pharmaceutical compositions including them | AVENTIS PHARMA S.A. (FR) | 2007-01-23 | — | — | US | claimed |
| US-20040110956-A1 | 3-aminoindazole derivatives, e.g., N-butyl-6-chloro-5-phenyl-1H-indazol-3-amine; treating diseases involving phosphorylation of the tau protein such as Alzheimer's disease, Parkinson's disease, and frontoparietal dementia | AVENTIS PHARMA S.A. (FR) | 2004-06-10 | — | — | US | claimed |
| EP-1537087-B1 | NOVEL AMINOINDAZOLE DERIVATIVES AS MEDICINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | AVENTIS PHARMA SA (FR) | 2012-11-28 | — | — | EP | disclosed |
| US-7582669-B2 | Aminoindazole derivatives as medicaments and pharmaceutical compositions including them | AVENTIS PHARMA SA (FR) | 2009-09-01 | — | — | US | disclosed |
| US-20070093479-A1 | NOVEL AMINOINDAZOLE DERIVATIVES AS MEDICAMENTS AND PHARMACEUTICAL COMPOSITIONS INCLUDING THEM | AVENTIS PHARMA S.A. (FR) | 2007-04-26 | — | — | US | disclosed |
| US-7166629-B2 | Aminoindazole derivatives as medicaments and pharmaceutical compositions including them | AVENTIS PHARMA S.A. (FR) | 2007-01-23 | — | — | US | disclosed |
| US-20040110956-A1 | 3-aminoindazole derivatives, e.g., N-butyl-6-chloro-5-phenyl-1H-indazol-3-amine; treating diseases involving phosphorylation of the tau protein such as Alzheimer's disease, Parkinson's disease, and frontoparietal dementia | AVENTIS PHARMA S.A. (FR) | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093479-A1 | NOVEL AMINOINDAZOLE DERIVATIVES AS MEDICAMENTS AND PHARMACEUTICAL COMPOSITIONS INCLUDING THEM | SUCNR1, CNR1, SIGMAR1 | GSK3B 3594/4885CDK1 1614/4885CDK2 2075/4885 |
| US-20040110956-A1 | 3-aminoindazole derivatives, e.g., N-butyl-6-chloro-5-phenyl-1H-indazol-3-amine; treating diseases involving phosphorylation of the tau protein such as Alzheimer's disease, Parkinson's disease, and frontoparietal dementia | OXSR1, OXER1, OXGR1 | GSK3B 464/4885CDK1 380/4885CDK2 709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.